Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance (PERSEUS)

9 de octubre de 2026 actualizado por: Simone Vanni, Azienda Ospedaliero-Universitaria Careggi

The PERSEUS Registry - Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance

PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy). It collects data generated during routine care across the whole course of the disease: pre-hospital care when available, emergency department presentation, the hospital stay (including bedside reassessments in the first 48 hours when performed as part of care) and follow-up up to 5 years. The registry has a retrospective cohort (patients diagnosed from 1 January 2023 until local ethics committee approval, with data taken from medical records) and a prospective cohort (consecutive patients enrolled after approval). Taking part in the registry does not change patient care: all tests and treatments are decided by the treating physicians. The registry aims to describe how acute PE is managed in everyday practice and how often patients die (from any cause and from PE), deteriorate hemodynamically, have recurrent venous thromboembolism or bleeding, and develop long-term complications such as chronic thromboembolic pulmonary hypertension. The database also supports ancillary analyses with separate pre-specified analysis plans, such as the evaluation of existing risk-stratification tools.

Descripción general del estudio

Descripción detallada

BACKGROUND AND SCIENTIFIC RATIONALE

Pulmonary embolism (PE) represents a major cause of emergency department (ED) presentation, critical care admission, and early mortality. Despite advances in diagnostic algorithms and therapeutic strategies, intermediate- and high-risk PE patients remain challenging to risk-stratify dynamically during the acute phase. Current prognostic tools often rely solely on baseline single-point parameters, neglecting acute pathophysiological changes during the initial 48 hours of treatment. The PERSEUS Registry is designed to bridge this gap by capturing comprehensive, granular real-world data spanning the acute presentation, dynamic in-hospital course, and long-term surveillance.

STUDY DESIGN AND COHORTS

Time perspective: ambispective (retrospective and prospective cohorts, described below).

PERSEUS is an observational, ambispective, multicenter registry comprising two distinct phases:

  1. Retrospective Phase (Historical Cohort): Includes consecutive adult patients diagnosed with acute PE from January 1, 2023, up to the date of local Ethics Committee approval at each participating site. Data are abstracted from medical records.
  2. Prospective Phase (Contemporary Cohort): Enrolls consecutive adult patients presenting with acute PE after local Ethics Committee approval, extending for a continuous enrollment period of 5 years. Data are collected during routine care.

STUDY SETTING AND CLINICAL CONTINUUM OF CARE

Data collection spans the entire continuum of clinical care across participating academic, tertiary, and regional hospitals:

  • Baseline Presentation (T0): Captures pre-hospital emergency medical service (EMS) data (initial vital signs, cardiac arrest, point-of-care ultrasound [POCUS], pre-hospital anticoagulation or thrombolysis), ED arrival parameters, clinical symptoms, arterial blood gas analysis, admission laboratory biomarkers (high-sensitivity troponin, BNP/NT-proBNP, lactate, D-dimer, renal function), electrocardiographic patterns, and multiorgan diagnostic imaging (CT pulmonary angiography [CTPA], complete echocardiography/POCUS, and compression venous ultrasound [CUS]).
  • Dynamic In-Hospital Reassessment (T1-T4): To capture real-world hemodynamic and respiratory trajectories, serial parameters documented during standard clinical monitoring are recorded across predefined temporal windows: T1 (3-6 hours), T2 (6-12 hours), T3 (12-24 hours), and T4 (24-48 hours). Parameters include serial vital signs, shock index, respiratory support modalities, serial lactate/troponin kinetics, echocardiographic right ventricular function changes, and need for escalating hemodynamic or respiratory support (vasopressors, inotropes, non-invasive ventilation, mechanical ventilation, or ECMO).
  • Hospital Discharge & Complications: Documents in-hospital adverse events, need for rescue reperfusion, procedural complications, bleeding events, length of stay, and vital status at discharge.
  • Follow-up Surveillance: Thirty-day status is ascertained from clinical records. Follow-up then reflects routine care at 3 and 12 months and annually thereafter up to 5 years (in-person visit, telemedicine, telephone contact or review of clinical documentation), with regional mortality registries used to ascertain vital status when needed. Follow-up collects all-cause survival, cause of death, VTE recurrence, major and clinically relevant non-major bleeding, persistent functional limitation (modified Rankin Scale, exertional dyspnea, six-minute walk test when performed) and the development of chronic thromboembolic pulmonary hypertension (CTEPH).

OUTCOMES

Outcome definitions and time frames are reported in the Outcome Measures section.

DATA MANAGEMENT, QUALITY ASSURANCE, AND ETHICAL GOVERNANCE

Data collection is centralized using an electronic Case Report Form (eCRF) deployed on the REDCap (Research Electronic Data Capture) platform hosted on secure institutional servers at Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).

  • Privacy and Data Segregation: Strict GDPR compliance is maintained. Patient data are pseudonymized at source by the local site investigator using site-specific Subject IDs. The decoding key linking the alphanumeric ID to personal identifiers is maintained exclusively at the local participating hospital under the responsibility of the local Principal Investigator.
  • Data Access Groups (DAGs): REDCap DAGs are enforced to compartmentalize site-level access, ensuring participating centers can exclusively view, enter, and edit their own center's records, with no unauthorized cross-center data visibility.
  • Quality Assurance: The eCRF includes built-in validation rules (range and logic checks). The coordinating center performs regular central monitoring for inconsistencies, outliers and missing data, and discrepancies are resolved with each center through a formal query process. The Steering Committee reviews enrollment, data quality and protocol adherence every 6 months.
  • Regulatory Framework: Protocol version 2.0 (7 May 2026) received a favourable opinion from the Comitato Etico Regione Toscana - Area Vasta Centro (CEAVC, register no. 30742_oss, meeting of 9 June 2026) for the sites of Azienda Ospedaliero-Universitaria Careggi and Azienda USL Toscana Centro. Participation of other national and international centers is subject to approval of a protocol amendment and of the competent local ethics committees. The study is conducted in accordance with the Declaration of Helsinki, Good Clinical Practice principles and applicable privacy regulations (including Article 110-bis of the Italian Privacy Code).

Tipo de estudio

De observación

Inscripción (Estimado)

5000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Simone Vanni, MD, PhD
  • Número de teléfono: +393666904459
  • Correo electrónico: simone.vanni@unifi.it

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Madrid, España
        • Reclutamiento
        • Hospital Universitario Ramón y Cajal
        • Contacto:
        • Investigador principal:
          • David Jiménez, MD, PhD
      • Lido di Camaiore, Italia
        • Reclutamiento
        • Ospedale Versilia - Azienda USL Toscana Nord Ovest
        • Contacto:
        • Investigador principal:
          • Giuseppe Pepe, MD
      • Naples, Italia, 80131
        • Reclutamiento
        • AORN Antonio Cardarelli
        • Contacto:
        • Investigador principal:
          • Angela Iannuzzi, MD
      • Perugia, Italia, 06129
        • Reclutamiento
        • Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia
        • Contacto:
        • Investigador principal:
          • Cecilia Becattini, MD, PhD
      • Pisa, Italia
        • Reclutamiento
        • Azienda Ospedaliero-Universitaria Pisana - Ospedale Cisanello
        • Contacto:
        • Investigador principal:
          • Lorenzo Ghiadoni, MD, PhD
      • Torino, Italia, 10126
        • Reclutamiento
        • AOU Città della Salute e della Scienza di Torino - Presidio Molinette
        • Contacto:
        • Investigador principal:
          • Fulvio Morello, MD
    • Tuscany
      • Bagno a Ripoli, Tuscany, Italia, 50012
        • Reclutamiento
        • Ospedale Santa Maria Annunziata - Azienda USL Toscana Centro
        • Contacto:
      • Borgo San Lorenzo, Tuscany, Italia, 50032
        • Reclutamiento
        • Nuovo Ospedale del Mugello - Azienda USL Toscana Centro
        • Contacto:
      • Empoli, Tuscany, Italia, 50053
        • Reclutamiento
        • Ospedale San Giuseppe - Azienda USL Toscana Centro
        • Contacto:
      • Florence, Tuscany, Italia, 50134
        • Reclutamiento
        • Azienda Ospedaliero-Universitaria Careggi
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Simone Vanni, MD, PhD
        • Sub-Investigador:
          • Matteo Gabriele Monda, MD
      • Florence, Tuscany, Italia, 50122
        • Reclutamiento
        • Ospedale Santa Maria Nuova - Azienda USL Toscana Centro
        • Contacto:
      • Florence, Tuscany, Italia, 50143
        • Reclutamiento
        • Ospedale San Giovanni di Dio (Torregalli) - Azienda USL Toscana Centro
        • Contacto:
      • Pescia, Tuscany, Italia, 51017
        • Reclutamiento
        • Ospedale Santi Cosma e Damiano - Azienda USL Toscana Centro
        • Contacto:
      • Pistoia, Tuscany, Italia, 51100
        • Reclutamiento
        • Ospedale San Jacopo - Azienda USL Toscana Centro
        • Contacto:
      • Prato, Tuscany, Italia, 59100
      • Warsaw, Polonia
        • Reclutamiento
        • Medical University of Warsaw - Infant Jesus Teaching Hospital
        • Contacto:
        • Investigador principal:
          • Piotr Pruszczyk, MD, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Consecutive adults with objectively confirmed acute pulmonary embolism diagnosed at participating hospitals, from emergency department presentation through hospitalization, including patients presenting with obstructive shock or cardiac arrest.

Descripción

Inclusion Criteria:

  • Age 18 years or older at the time of presentation.
  • Objectively confirmed diagnosis of acute pulmonary embolism (PE), with or without concomitant deep vein thrombosis (DVT) of the lower or upper extremities, confirmed by at least one of the following methods:
  • Computed tomography pulmonary angiography (CTPA) demonstrating intraluminal filling defects in the pulmonary arterial tree;
  • Ventilation/perfusion (V/Q) lung scintigraphy demonstrating high-probability mismatch;
  • Conventional catheter-directed pulmonary angiography;
  • In hemodynamically unstable patients (obstructive shock or cardiac arrest) in whom definitive imaging is not feasible: bedside point-of-care ultrasound showing clear signs of right ventricular overload together with proximal deep vein thrombosis, or mobile right heart thrombi.
  • For the retrospective cohort: availability of medical records documenting clinical presentation and index diagnostic work-up at baseline (T0). The absence of serial reassessment timepoints (T1-T4) does not constitute an exclusion criterion.
  • Written informed consent obtained from the patient or legal surrogate, or waiver/exception under Article 110-bis of the Italian Privacy Code (and applicable institutional ethical clearance) for deceased or untraceable patients.

Exclusion Criteria:

  • Current active enrollment in an interventional experimental drug trial (blinded randomized clinical trial) where active drug allocation or protocol-mandated therapeutic regimen is unknown.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: OTHER

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Adults with acute pulmonary embolism

Consecutive adults with objectively confirmed acute pulmonary embolism, in two cohorts: a retrospective cohort (diagnoses from 1 January 2023 until local ethics committee approval; data abstracted from medical records) and a prospective cohort (consecutive enrollment after approval, for 5 years; data collected during routine care).

Observational registry. Diagnostic and therapeutic management (laboratory tests, imaging, bedside ultrasound, anticoagulation, reperfusion and hemodynamic support) is entirely at the discretion of the treating physicians, according to routine institutional pathways and international guidelines. The registry only collects data generated in routine care.

Otros nombres:
  • Routine Clinical Practice, Usual Care

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
All-cause mortality at 30 days
Periodo de tiempo: 30 days after diagnosis

Proportion of patients who die from any cause within 30 days of the objectively confirmed diagnosis of acute pulmonary embolism. Vital status is ascertained from hospital records, review of clinical documentation and, when needed, regional mortality registries.

30 days after diagnosis
PE-related mortality at 30 days
Periodo de tiempo: 30 days after diagnosis

Proportion of patients whose death within 30 days is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism (PE). Fatal PE is defined as death occurring after objectively confirmed PE (index or recurrent event) in the absence of other identifiable causes, or confirmed at autopsy. For deaths occurring at home, information on the cause of death is actively sought.

30 days after diagnosis

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Hemodynamic decompensation
Periodo de tiempo: From diagnosis to hospital discharge or day 30, whichever comes first

Proportion of patients with new occurrence, after the initial assessment, of at least one of: persistent hypotension (systolic blood pressure <90 mmHg for 15 minutes or longer) or shock; need for continuous vasopressor or inotrope infusion; invasive mechanical ventilation; cardiac arrest; rescue reperfusion therapy (systemic, catheter-directed or surgical) for clinical deterioration. Reperfusion given as the initial treatment strategy is not counted as an event.

From diagnosis to hospital discharge or day 30, whichever comes first
All-cause mortality during follow-up
Periodo de tiempo: 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients who die from any cause during follow-up.

3 months, 12 months, and annually up to 5 years after diagnosis
PE-related mortality during follow-up
Periodo de tiempo: 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients whose death during follow-up is adjudicated as a direct consequence of the index or a recurrent pulmonary embolism, as defined for the 30-day PE-related mortality outcome.

3 months, 12 months, and annually up to 5 years after diagnosis
Recurrent venous thromboembolism
Periodo de tiempo: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients with any new episode of pulmonary embolism or deep vein thrombosis (lower or upper limb, proximal or distal) confirmed by objective testing. Superficial vein thrombosis is not counted.

30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Major bleeding (ISTH criteria)
Periodo de tiempo: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients with major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH): overt bleeding that is fatal; or occurs in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome); or causes a fall in hemoglobin of 2 g/dL (1.24 mmol/L) or more, or leads to transfusion of two or more units of whole blood or red cells. Major bleeding is additionally classified as life-threatening if it is extracranial bleeding causing shock or intracranial hemorrhage with a Glasgow Coma Scale score below 14.

30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Clinically relevant non-major bleeding
Periodo de tiempo: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients with bleeding not meeting the criteria for major bleeding but requiring medical intervention, unscheduled contact with a physician, or temporary cessation of antithrombotic therapy.

30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Chronic thromboembolic pulmonary hypertension (CTEPH)
Periodo de tiempo: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

Proportion of patients with CTEPH diagnosed during routine follow-up: mean pulmonary arterial pressure >20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg and pulmonary vascular resistance >2 Wood units at right heart catheterization, with mismatched perfusion defects after at least 3 months of therapeutic anticoagulation (2022 ESC/ERS criteria). Diagnostic tests are performed only when clinically indicated.

30 days, 3 months, 12 months, and annually up to 5 years after diagnosis
Persistent functional limitation after pulmonary embolism (post-PE syndrome)
Periodo de tiempo: 30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

Persistent or worsened exertional dyspnea compared with pre-event status, modified Rankin Scale score, and six-minute walk distance when performed in routine care.

30 days, 3 months, 12 months, and annually up to 5 years after diagnosis

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Simone Vanni, MD, PhD, Azienda Ospedaliero-Universitaria Careggi / University of Florence
  • Director de estudio: Matteo Gabriele Monda, MD, Azienda Ospedaliero-Universitaria Careggi / University of Florence

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de junio de 2026

Finalización primaria (Estimado)

1 de julio de 2031

Finalización del estudio (Estimado)

1 de julio de 2032

Fechas de registro del estudio

Enviado por primera vez

28 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

28 de septiembre de 2026

Publicado por primera vez (Actual)

2 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

15 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Pseudonymized individual participant data underlying published results may be shared with qualified researchers for methodologically sound proposals that fall within the scientific scope of the registry and do not overlap with analyses planned by the PERSEUS investigators. Sharing requires approval by the PERSEUS Steering Committee, approval by the competent ethics committee and a data transfer agreement with Azienda Ospedaliero-Universitaria Careggi, in compliance with the GDPR and the Italian Privacy Code.

Marco de tiempo para compartir IPD

Data will become available beginning 12 months after formal publication of the primary registry outcomes manuscript and will remain accessible for a period of 5 years.

Criterios de acceso compartido de IPD

Access requests must be submitted in writing to the Principal Investigator (simone.vanni@unifi.it) and the PERSEUS Steering Committee, including a detailed scientific protocol and statistical analysis plan. Proposals will be evaluated for scientific merit, feasibility, ethical compliance, and non-redundancy by the Steering Committee. Prior to data release, requestors and their home institutions must sign a formal Data Transfer Agreement (DTA) with Azienda Ospedaliero-Universitaria Careggi and obtain appropriate local ethical approval.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir